Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: A double-blind, active-comparator trial

Table 2 Gastrointestinal outcomes: Patient assessment in constipation

Outcome measure	Intent to treat			Completers
	Lubiprostone	Senna	P value	Lubiprostone	Senna	P value
	n = 28	n = 28		n = 21	n = 22
PAC-SYM
Baseline	0.72 ± 0.56	0.93 ± 0.77	0.10	0.76 ± 0.60	0.95 ± 0.81	0.25
Day 7	0.51 ± 0.41	0.63 ± 0.59	0.06	0.57 ± 0.44	0.59 ± 0.58	0.35
Change	-0.22 ± 0.57	-0.29 ± 0.58	0.89	-0.20 ± 0.60	-0.36 ± 0.61	0.61
PAC-QOL
Baseline	1.50 ± 0.64	1.41 ± 0.73	0.63	1.42 ± 0.55	1.32 ± 0.66	0.63
Day 7	1.66 ± 0.59	1.83 ± 0.79	0.35	1.67 ± 0.56	1.82 ± 0.77	0.35
Change	0.99 ± 0.78	0.42 ± 0.84	0.30	0.25 ± 0.78	0.50 ± 0.80	0.61

Data are expressed as absolute numbers (percentage) or mean ± SD. PAC-SYM: Patient assessment of constipation (PAC)-symptoms; PAC-QOL: PAC-quality of life.